glp-1 lilly FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and hormone receptors - Eli Lilly is now pharma's top
Description
It's unclear exactly when that approval could be, but it's safe to say that the pill will enter the market sometime in 2026
Escalating Specialty Drug and GLP-1 Costs And the Strategies to Fight Them in 2025 and Beyond Managing pharmacy drug benefits is complex and high-touch
Credit W Scott Butsch and colleagues
Prior studies involving diet and bariatric surgery have already demonstrated meaningful reductions in knee pain and disability following substantial weight reduction
